title: Hyperprolactinaemia.
abstract: Hyperprolactinaemia is a frequent cause of reproductive problems encountered in clinical practice. A variety of pathophysiological conditions can lead to hyperprolactinaemia; therefore, pregnancy, drug effects, hypothyroidism and polycystic ovary syndrome should be excluded before investigating for prolactin-secreting pituitary tumours. Prolactinomas are mainly diagnosed in women aged 20-40 years. They present with clinical features of hyperprolactinaemia (galactorrhoea, gonadal dysfunction), and more rarely with large tumours, headache and visual field loss due to optic chiasm compression. Medical therapy with dopamine agonists is the treatment of choice for both micro- and macroprolactinomas. Tumour shrinkage and restoration of gonadal function are achieved in the majority of cases with dopamine agonists. A trial of withdrawal of medical therapy may be considered in many patients with close follow-up. Pituitary surgery and radiotherapy currently have very limited indications. Pregnancies in patients with prolactinomas need careful planning and close monitoring.
authors: Department of Endocrinology, Manchester Royal Infirmary, Manchester M13 9WL, UK.
authors: V K B
authors: VK
authors: Prabhakar
authors: J R E
authors: JR
authors: Davis
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000627:therapeutic use; D004351:Drug Resistance; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D010911:Pituitary Neoplasms / Q000150:complications / Q000188:drug therapy; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D015175:Prolactinoma / Q000150:complications / Q000188:drug therapy
chemical_list: D000970:Antineoplastic Agents; D018491:Dopamine Agonists